Rapid and generic identification of influenza A and other respiratory viruses with mass spectrometry  by Majchrzykiewicz-Koehorst, Joanna A. et al.
R
v
J
A
F
a
b
c
T
A
R
R
1
A
A
K
M
M
L
I
I
V
1
b
c
i
w
i
i
v
r
v
v
A
h
0Journal of Virological Methods 213 (2015) 75–83
Contents lists available at ScienceDirect
Journal of Virological Methods
journa l homepage: www.e lsev ier .com/ locate / jv i romet
apid and generic identiﬁcation of inﬂuenza A and other respiratory
iruses with mass spectrometry
oanna A. Majchrzykiewicz-Koehorsta, Esther Heikensb, Hein Tripa, Albert G. Hulsta,
d L. de Jonga, Marco C. Viveenb, Norbert J.A. Sedeea, Jan van der Plasc,
rank E.J. Coenjaertsb, Armand Paauwa,∗
Netherlands Organization for Applied Scientiﬁc Research TNO, Department of CBRN Protection, Lange Kleiweg 137, 2288 GJ Rijswijk, The Netherlands
Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
Expert Centre Force Health Protection, Health Care Division, Support Command, Ministry of Defence, Korte Molenweg 3, Building 37, 3941 PW Doorn,
he Netherlands
rticle history:
eceived 29 May 2014
eceived in revised form
3 November 2014
ccepted 18 November 2014
vailable online 8 December 2014
eywords:
ass spectrometry
ALDI-TOF MS
C–MS/MS
nﬂuenza virus
a b s t r a c t
The rapid identiﬁcation of existing and emerging respiratory viruses is crucial in combating outbreaks
and epidemics. Matrix-assisted laser desorption/ionization time-of-ﬂight mass spectrometry (MALDI-
TOF MS) is a rapid and reliable identiﬁcation method in bacterial diagnostics, but has not been used
in virological diagnostics. Mass spectrometry systems have been investigated for the identiﬁcation of
respiratory viruses. However, sample preparation methods were laborious and time-consuming. In this
study, a reliable and rapid sample preparationmethodwas developed allowing identiﬁcation of cultured
respiratory viruses. Tenfold serial dilutions of ten cultures inﬂuenza A strains,mixed samples of inﬂuenza
A virus with human metapneumovirus or respiratory syncytial virus, and reconstituted clinical samples
were treated with the developed sample preparation method. Subsequently, peptides were subjected
to MALDI-TOF MS and liquid chromatography tandem mass spectrometry (LC–MS/MS). The inﬂuenza
A strains were identiﬁed to the subtype level within 3h with MALDI-TOF MS and 6h with LC–MS/MS,dentiﬁcation
irological diagnosis
excluding the culturing time. The sensitivity of LC–MS/MS was higher compared to MALDI-TOF MS. In
addition, LC–MS/MS was able to discriminate between two viruses in mixed samples and was able to
identify virus from reconstituted clinical samples. The development of an improved and rapid sample
preparation method allowed generic and rapid identiﬁcation of cultured respiratory viruses by mass
spectrometry.
ublis© 2014 The Authors. P
. Introduction
Respiratory viruses are a major cause of infections, natural out-
reaks, and epidemics. Approximately 200 million cases of viral
ommunity-acquired pneumonia occur every year: 100 million
n children and 100 million in adults (Ruuskanen et al., 2011). A
ide range of viruses, including current circulating subtypes of
nﬂuenzaAvirus (inﬂuenzaA(H1N1)pdm09and inﬂuenzaAH3N2),
nﬂuenza B virus, respiratory syncytial virus (RSV), parainﬂuenza
iruses, adenovirus, and rhinovirus, have been implicated in respi-
atory tract infections in past decades. In the last ten years, new
iruses have emerged as severe acute respiratory syndrome (SARS)
irus, Middle East respiratory syndrome (MERS), avian inﬂuenza
(H5N1) virus, human metapneumovirus (hMPV), coronaviruses
∗ Corresponding author. Tel.: +31 88 866 3766.
E-mail address: armand.paauw@tno.nl (A. Paauw).
ttp://dx.doi.org/10.1016/j.jviromet.2014.11.014
166-0934/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unhed by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
NL63andHKU1, andhumanbocavirus. Rapid identiﬁcationof exist-
ing and emerging respiratory viruses is of the utmost importance in
combating outbreaks and epidemics, and starting early therapy and
prophylaxis. Currently, cell culture, serology, and real-time reverse
transcription-polymerasechain reaction (rRT-PCR)areused inviro-
logical diagnostics. However, there are a few drawbacks with
these techniques: (i) serology and rRT-PCR-based assays are tar-
get directed and thus potentially miss non-selected or emerging
pathogenic viruses (Binnicker et al., 2013; Yang et al., 2014); (ii)
culturing is time consuming; (iii) serology-based assays are not
applicable in the acute phase and/or have low sensitivity. Fur-
thermore, multiple tests are needed to detect and subtype mixed
infections.
Matrix-assisted laser desorption/ionization-time of ﬂight mass
spectrometry (MALDI-TOF MS) is a generic technique that can
rapidly identify cultured microorganisms (Seng et al., 2009; van
Veen et al., 2010). The analysis of bacteria by mass spectrometry
(MS) has made great progress over the last two decades, and it is
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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mployed in many hospitals as a rapid and reliable alternative to
raditional identiﬁcation methods. Thus far, mass spectrometry-
ased methods have not been used for virological diagnostics.
owever, it has been shown that puriﬁed inﬂuenza virus particles
ould be identiﬁed with either MALDI-TOF MS or MALDI Fourier
ransform Ion Cyclotron Resonance MS (MALDI-FT-ICR MS). Iden-
iﬁcation was based on the proteolytic digestion of concentrated
nd puriﬁed viral samples and on mass spectrometry analysis of
he speciﬁc peptide mass proﬁle. The sample preparation methods
sed in these studies included virus concentration and/or puriﬁ-
ation with either ultracentrifugation, differential centrifugation,
recipitation, ﬁltration, isolationof viral particles or protein(s)with
n afﬁnity capture immunoassay or gel electrophoresis (Downard
t al., 2009; Schwahn et al., 2009a,b, 2010a,b; Chou et al., 2011; Jang
t al., 2011; Nguyen and Downard, 2013; Fernandes and Downard,
014). These sample preparation procedures were laborious and
ften time consuming (up to 24h) and are therefore not applicable
or high-throughput virological diagnostics.
The aim of this study was to develop a rapid, generic and robust
ample preparationmethod forMALDI-TOFMS and LC–MS/MS that
ill enable reliable and fast identiﬁcation of respiratory viruses. For
his purpose, cultured inﬂuenza A virus strains and mixed samples
f inﬂuenza A viruswith hMPV or RSVwere treatedwith the devel-
ped preparation method. Subsequently, obtained peptides were
ubjected to MALDI-TOFMS and LC–MS/MS for analyses. The iden-
iﬁcation of the respiratory viruses was based on peptide sequence
ifferences in abundant viral proteins. To conﬁrm correct identiﬁ-
ation of peptides bymass spectrometry, the amino acid sequences
ere compared to the corresponding DNA sequences, obtained by
equencing of the viruses. Finally, to determine the sensitivity of
he in-house developed method the titers of cultured viruses were
etermined with rRT-PCR.
. Materials and methods
.1. Ethics statement
All of the clinical inﬂuenza strains, anonymized from routine
iagnostics, originated from a collection at the University Medical
enter Utrecht (UMCU). Collection of the samples and analysis of
he isolated virus strainswere approved by the localMedical Ethics
ommittee of the UMCU. The institutional review board (IRB) con-
rmed (protocol 12/320) that the viral strains were not regarded
s patient-owned material; consequently, the use of these strains
as not restricted by Dutch law (“Law Medical Scientiﬁc Research
ith People”, WMO; art. 1b).
.2. Viruses
Nasopharyngeal swabs and tracheal aspirates were collected
etween 2009 and 2011 from patients who were hospitalized
ith respiratory distress symptoms in the wards of the UMCU
Table S1). The collected samples were cultured immediately in
ither LLC-MK2 or HEp2 cell lines and were routinely checked for
ytopathological effect (CPE) formation. The samples exhibiting
peciﬁc CPE in 80% of the cells and testing positive for respiratory
iruses by real-time PCR were harvested and stored at −80 ◦C.
Next, eight inﬂuenza A H1N1 strains (designated here as
M1456, BM1457, and BM1480 through BM1485) and two
nﬂuenzaAH3N2strains (designatedhere asBM1454andBM1455)
ere cultured in LLC-MK2 cells in the presence of EMEM (Eagle’s
inimal essential medium) with trypsin at 37 ◦C (Table S1). In
ddition, hMPV (designated here as BM1460) and RSV type A (des-
gnated here as BM1450) were cultured in LLC-MK2 cells in the
resence of EMEM with trypsin at 37 ◦C and in HEp2 cells in the
resence of DMEM (Dulbecco’s modiﬁed Eagle medium) with 5%f Virological Methods 213 (2015) 75–83
FBS (fetal bovine serum) at 33 ◦C, respectively (Table S1). Subse-
quently, the culture supernatantswere collected, and the cell debris
was removed by centrifugation (239× g, 10min). Aliquots were
frozen at −80 ◦C and were used without further puriﬁcation steps.
2.3. Viral RNA extraction, cDNA synthesis, and rRT-PCR
To determine the sensitivity of the in-house developed sample
preparationmethod the titers of cultured viruses were determined
with rRT-PCR by using a standard curve. This standard curve was
developed by counting virus particles using electron microscopy
and by subsequently performing PCR.
Viral RNA extraction and PCR were performed according to
previously described protocols (Tan et al., 2012). In short, viral
genomic RNA was isolated using a MagnaPure LC total nucleic
acid kit, according to the manufacturer’s guidelines (Roche Diag-
nostics,Mannheim, Germany).Murine encephalomyocarditis virus
wasusedasan internal control. Reverse transcriptionof the isolated
viral RNA was performed using a MultiScribe reverse transcrip-
tase kit and random hexamers (Applied Biosystems, Foster City,
CA, USA), according to the manufacturer’s guidelines. PCR primers
andprobesweredesignedon thebasis of highly conservedgenomic
regionsof theM1gene for inﬂuenzaAand theNgene for bothhMPV
andRSVA, and theseprimers andprobeswereused for the typingof
the viral strains. The primers and probes used are listed in Table S2.
cDNA samples were analyzed in a 25l reaction mixture, con-
taining 10l of cDNA, TaqMan universal PCR master mix (Applied
Biosystems, ABI), primers and ﬂuorogenic probes labeled with the
5′ reporter dye 6-carboxy-ﬂuorescein (FAM), and the 3′ quencher
dye 6-carboxy-tetramethyl-rhodamine (TAMRA). Ampliﬁcation
and detection were performed with an ABI 7500 system for 2min
at 50 ◦C, 10min at 95 ◦C, and 45 cycles of 15 sec at 95 ◦C and 1min
at 60 ◦C. The samples were assessed for the presence of possible
inhibitors of the ampliﬁcation reaction using the indicated internal
control, the signals ofwhichhad to rangewithina clear-cut interval.
2.4. Viral genomic cDNA synthesis and sequencing
To conﬁrm the presence and amino acid sequence accuracy of
the identiﬁed peptides, six of the clinical isolates were sequenced.
The RSV strain (BM1450) with accession number JQ901450 was
sequenced previously (Tan et al., 2012). For sequencing pur-
poses, hMPV (BM1460) and inﬂuenza (BM1454, BM1456, BM1457,
BM1480, and BM1483) PCR fragments were obtained by fractional
ampliﬁcation of MagNAPure LC genomic RNA isolates, using the
Superscript III one-step RT-PCR System with Platinum Taq High
Fidelity kit (Invitrogen) and a 9800 Fast thermal cycler (ABI),
according to the manufacturers’ protocols. Unlike hMPV and RSV,
inﬂuenza virus contains a segmented genome consisting of 8 seg-
ments. All of the segments were completely ampliﬁed and puriﬁed
from an agarose gel prior to fractional ampliﬁcation, as previ-
ously described (Zhou et al., 2009). The PCR products were applied
to a 1% agarose gel and were puriﬁed from the gel with a Gene
JET Gel Extraction Kit (Thermo Fisher Scientiﬁc, Landsmeer, the
Netherlands), according to the manufacturer’s protocol. The iso-
lated fragments were used for whole-genome sequencing.
The hMPV (BM1460) and inﬂuenza strains (BM1454, BM1456,
BM1457, BM1480, and BM1483) listed in Table S1 were sequenced
according to the whole-genome sequence protocol described
recently, using the conventional Sanger technique (Tan et al.,
2012). Fragments ranging between 650 and 1400 nucleotides were
sequenced with an ABI 3730 48-capillary DNA analyzer, using
Big-Dye Terminator 3.1 (ABI). The resulting sequence information
was assembled into an hMPV whole-genome sequence through
alignment with the corresponding reference sequence (GenBank:
FJ168779; http://www.ncbi.nlm.nih.gov/genbank/index.html)
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sing Seqman software (DNASTAR lasergene 8); a similar approach
as followed for the inﬂuenza strains. Table S3 provides an
verview of the primers used for inﬂuenza, hMPV, and RSV
equencing. The DNA and amino acid sequences of the sequenced
trains are provided in Supplementary Data.
.5. Sample preparation of cultured viruses
The starting titers of the viral cultures are shown in Table
1. The starting titers for the inﬂuenza strains and RSV appeared
oughly similar (∼3×1011 copies/ml), but the starting titer for
MPV was 100-fold lower. Tenfold serial dilutions for all of the
trains (inﬂuenza A virus, RSV, and hMPV) were prepared in
yMol medium (Copan Italia, Brescia, Italy). CyMol is a collection,
ransport, and preservation medium for cells (cytology analy-
is), viruses, and nucleic acids (PCR-based assays) (Luinstra et al.,
011a). Subsequently, 200l of each tenfold dilution step was
reated according to the in-house developed sample pretreatment
rotocol, as follows. A 200l aliquot was mixed with 25l of a
.5% stock solution of RapiGest (Waters Corporation, Milford, CT,
SA) and was incubated for 7min at 95 ◦C. Next, DL-dithiothreitol
DTT, Sigma–Aldrich) and acetonitrile (LC–MS Chromasolv,
igma–Aldrich)were added to5mMand to25%ﬁnal concentration,
espectively. Reduction and precipitation of the proteins were per-
ormedunder controlledmicrowave radiation in aRapid Enzymatic
igestionSystem(REDS;HudsonSurfaceTechnology [HST] Inc.,Old
appan, NJ, USA) at 60 ◦C and 400W for 10min. The subsequent
arbamidomethylation of cysteine residues was executed at 37 ◦C
nd 400W for 5min in REDS, after the addition of iodoacetamide
IAA; Sigma–Aldrich) to a 12.5mM ﬁnal concentration. Next, the
roteinaceous particles were precipitated at 20,800× g for 7min,
nd the supernatants were discarded. The pellets were suspended
n 40l of 50mM ammonium bicarbonate (Sigma–Aldrich) con-
aining 4g/ml modiﬁed and TPCK-treated trypsin from bovine
ancreas (Sigma–Aldrich). Digestion was performed for 10min in
EDS at 37 ◦C and 400W andwas terminated by the addition of tri-
uoroacetic acid (TFA) to 1% ﬁnal concentration. After incubation
t 37 ◦C for 30min, the RapiGest precipitateswere removed by cen-
rifugation, and the supernatants were ﬁltered through aMicrocon
M-10 ﬁlter (10MWCO,MerckMillipore Ltd.; Co. Cork, Ireland). All
f the samples were prepared at least twice.
For the analysis of mixtures of two different viral culture
amples, each tenfold dilution of inﬂuenza A H3N2 (BM1454) or
1N1 (BM1456) was mixed with the corresponding dilution of the
SV (BM1450) or hMPV (BM1460) culture samples, respectively,
ollowed by the exact sample preparation procedure described
bove. All the samples were prepared at least twice. To test
hether human proteins present in clinical material interfere with
he developed sample preparation method or identiﬁcation by
C–MS/MS, reconstituted throat swabs were included. A swab that
as rubbedaround the tonsils of avolunteerwaswashedbyvortex-
ng the swab inCyMolmedium. Subsequently, this so-called clinical
ample was spiked with dilutions of cultured inﬂuenza A virus
BM1454, BM1456), RSV (BM1450), or hMPV (BM1460). The same
amplepreparation andLC–MS/MSanalysis procedure asdescribed
bove were performed on these reconstituted clinical samples. All
ested samples were prepared at least twice.
.6. MALDI-TOF MS analysis and database search
A 10l aliquot of each sample was desalted on a C18 ZipTip
Merck Millipore Ltd.), and the peptides were eluted with 1l of
0% acetonitrile containing 10mg/ml-cyano-4-hydroxycinnamic
cid (HCCA) and 2.5% triﬂuoroacetic acid (TFA). Elution was per-
ormed directly onto the MALDI target (MTP Polished steel, Bruker
altonics, GmbH, Bremen, Germany), and the droplets weref Virological Methods 213 (2015) 75–83 77
air-dried. Spectra were recorded in reﬂector mode, using a MALDI-
TOF MS instrument (Autoﬂex III, Bruker). Each spectrum was
acquired by averaging 2000 laser shots (at 40% laser power) across
a mass range of m/z 500–4000 followed by noise reduction. The
instrument was mass calibrated with an external peptide standard
(Peptide Calibration Standard, Bruker). The spectra were analyzed
with FlexAnalysis and Biotools (Bruker). Internal calibration was
performed using identiﬁed peptides derived from viral nucleopro-
tein or trypsin. From the spectra, peak lists were generated and
searched against the NCBI virus database (database collection of
viruses: 2013.06.29) usingMASCOT, version 2.2.04 (Matrix Science,
London, UK) with a mass tolerance of 70ppm (Perkins et al., 1999;
Koenig et al., 2008). The carbamidomethylationof cysteine residues
and oxidation ofmethioninewere included in the calculations, and
up to two missed cleavages were permitted. The MASCOT scoring
systemwas used to determine protein expectation values that cor-
responded to the number of matches that were expected to occur
by chance alone. The highest expectation value was considered
the best match. All of the assays were performed at least twice.
In separate experiments, the peaks that were identiﬁed initially
as nucleoprotein (NP) peptides of inﬂuenza A were subsequently
conﬁrmed by MALDI-TOF MS/MS. The MS/MS spectra were
recorded in the reﬂector mode using LIFT technology (Bruker).
2.7. LC–MS/MS analysis and database search
The digests were analyzed by LC–MS/MS using a nano-Advance
LC system (Bruker) coupled to a Q-TOF mass spectrometer (maXis
impact, Bruker). A 5l aliquot of each digested samplewas injected
onto a Magic C18AQ UHPLC NanoTrap column (C18, 100m
ID×100mm, 5m, 200 A˚, Bruker) and was washed with loading
solvent H2O (0.2% formic acid) for 5min at a ﬂow rate of 4l/min.
Following valve switching, the peptides were separated on aMagic
C18AQ analytical column (100m ID×150mm, C18, 3m, 200 A˚,
Bruker) at a constant ﬂow of 800nl/min. The peptide elution gradi-
entwas from98%A (H2Owith 0.1% formic acid) to 45%B (CH3CN) in
30min, followed by an increase to 95% B for 5min. Optima LC–MS
H2O (0.1% formic acid; Fisher Scientiﬁc)wasused for the LC–MS/MS
studies.
The nanoLC systemwas coupled to themass spectrometer using
a CaptiveSpray (Bruker) ionization source. The spray voltage was
set at 1.4–1.6 kV, and the temperature of the heated capillary was
set at 150 ◦C. The eluting peptides were analyzed using the data-
dependentMS/MSmode. The tenmost abundant ions (charge state
2+, 3+, and 4+) in anMS spectrum (400–1400m/z) were selected for
data-dependent MS/MS analysis by collision-induced dissociation,
using nitrogen as the collision gas. TheMS/MS scans were acquired
over a mass range of 100–2000 m/z.
Peak lists were generated using DataAnalysis software, version
4.1 (Bruker), and the lists were exported asMASCOTGeneric (MGF)
ﬁles. These ﬁles were searched against the NCBI database (taxon-
omy: viruses) with the MASCOT search algorithm (MASCOT 2.2.04,
Matrix Science). A mass tolerance of 50ppm and an MS/MS toler-
ance of 25 mmu were used. Up to two missed cleavages for trypsin
were allowed; carbamidomethylcysteine was selected for ﬁxed
modiﬁcation and oxidation of methionine for variable modiﬁca-
tion. Only signiﬁcant protein hits with at least two unique peptides
with a score greater than 20 were selected.
3. Results
3.1. Sample preparation and identiﬁcation of inﬂuenza A viruses
by MALDI-TOF MS
Ten inﬂuenzaA virus strains, isolated fromhospitalized patients
and characterized to the subtype level (eight H1N1 and twoH3N2),
78 J.A. Majchrzykiewicz-Koehorst et al. / Journal of Virological Methods 213 (2015) 75–83
Table 1
Identiﬁed inﬂuenza A viruses based on nucleoprotein peptide detection by MALDI-TOF MS.
Straina Subtype Id. scoreb Seq. cov.c (%) Identiﬁed as nucleoprotein ofd (subtype/host)
BM1454 H3N2 90 30 Inﬂuenza A virus (H3N2/human)
BM1455 H3N2 108 35 Inﬂuenza A virus (H3N2/human)
BM1456 H1N1 91 37 Inﬂuenza A virus (H1N1/human)
BM1457 H1N1 89 31 Inﬂuenza A virus (H1N1/human)
BM1480 H1N1 95 41 Inﬂuenza A virus (H1N1/swine)
BM1481 H1N1 102 36 Inﬂuenza A virus (H1N1/human)
BM1482 H1N1 89 34 Inﬂuenza A virus (H1N1/human)
BM1483 H1N1 93 36 Inﬂuenza A virus (H1N1/swine)
BM1484 H1N1 95 32 Inﬂuenza A virus (H1N1/swine)
BM1485 H1N1 103 37 Inﬂuenza A virus (H1N1/human)
a Viral strains were tested at approximately 1×109 genome copies in the total volume of each sample deposited onto the MALDI plate and analyzed.
b Protein identiﬁcation score given by MASCOT. A score ≥76 was considered signiﬁcant identiﬁcation.
c Sequence coverage of nucleoprotein, as speciﬁed by MASCOT in percentage, based on the number of amino acids covered by mass values (peptides) matched with the
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d The nucleoprotein that received the highest MASCOT score is shown. The inﬂue
n detection of nucleoprotein peptides.
ere cultured inLLC-MK2cells, resulting inviral titers ranging from
.1 to 4.3×1011 genome copies/ml (Table S1). After the removal
f cell debris, tenfold dilution series of the viral cultures were pre-
ared in CyMolmedium. Each dilutionwas treated according to the
n-house developed sample preparation procedure. Subsequently,
eptides were subjected to MALDI-TOF MS and were analyzed
y MASCOT software. In two independent experiments, all of the
ested inﬂuenza A strains (eight H1N1 and two H3N2) were cor-
ectly identiﬁed based on the recognition of peptides derived from
ucleoprotein (Table 1 and Fig. 1). The ten inﬂuenza A strains were
ot only identiﬁed to their type, but also correctly identiﬁed to
heir subtype (Table 1). The entire procedure, i.e. the dilution series
reparation followed by the treatment according to the in-house
rotocol, data analysis and the obtaining of results, was performed
ithin 3h for ten samples.
The identiﬁcation limit at which the viral strains were correctly
yped and subtyped appeared to be 1×109 viral genome copies in
able 2
eptides derived from inﬂuenza A nucleoprotein and detected by MALDI-TOF MS.
H1N1 strains Observed [M+H]+
SALILR 672.4
NLPFER 775.4
QDATEIR 832.4
AMMDQVR 850.4
KTGGPIYR 891.5
SRYWAIR 951.5
GKFQTAAQR 1006.5
MVLSAFDER 1067.5
GVGTIAMELIR 1159.7
LIQNSITIER 1186.7
MVLSAFDERR 1223.6
MCSLMQGSTLPR 1380.6
ELILYDKEEIR 1420.7
ATVMAAFSGNNEGR 1424.6
ELILYDKEEIRR 1576.9
NPGNAEIEDLIFLAR 1671.9
ASAGQISVQPTFSVQR 1675.8
MMESAKPEDLSFQGR 1725.8
SQLVWMACHSAAFEDLR 2020.9
ESRNPGNAEIEDLIFLAR 2044.0
SYEQMETGGERQDATEIR 2099.9
SCLPACVYGLAVASGHDFER 2209.0
DS 775.4; 1424.6
DS 1186.7; 1067.5
LLQNSQVVSLMRPNENPAHK 2275.2
GVQIASNENVETMDSNTLELR 2320.2
eptides with a S/N of ≥6 are listed. These peptides were identiﬁed in tested viral strain
nto a MALDI plate and analyzed.
D, peptide not detected.
S, detected sequence in the tested strains but in another peptide due to missed cleavageubtype should be considered as an indication because the identiﬁcation was based
the total sample volume deposited onto a MALDI plate for analy-
sis (corresponding to a CT value of approximately 24; Table 1). At
this viral titer, more than 20 mass peaks could be assigned with
high signiﬁcance to peptides derived from nucleoprotein (Table 2).
The identity of approximately half of these peptide peaks was
conﬁrmed by MALDI-TOF MS/MS (data not shown). The inten-
sities of the remaining peptide peaks assigned to nucleoprotein
were too low for MS/MS analysis. The genomes of ﬁve inﬂuenza A
strains, namely BM1454, BM1456, BM1457, BM1480, and BM1483,
were sequenced, and the amino acid sequences of all of the iden-
tiﬁed peptides were found to be encoded in the corresponding
genome sequences (Supplementary Data, genomic and amino acid
sequences of sequenced strains).Of the other proteins that constitute the viral proteome,
only M1-derived peptides were identiﬁed occasionally (data not
shown). The MS spectra also contained peaks from abundant
non-viral proteins derived from cell lysates, such as actin and
H3N2 strains Observed [M+H]+
SALILR 672.4
DS 2184.1
QNATEIR 831.4
AMVDQVR 818.4
KTGGPIYR 891.5
SGYWAIR 852.4
GKFQTAAQR 1006.5
MVLSAFDER 1067.5
ND –
DS 2207.2
MVLSAFDERR 1223.6
MCSLMQGSTLPR 1380.6
ELVLYDKEEIR 1406.7
STIMAAFTGNTEGR 1455.7
ELVLYDKEEIRR 1562.8
NPGNAEIEDLIFLAR 1671.9
ASAGQTSVQPTFSVQR 1663.9
MMEGAKPEEVSFR 1510.7
SQLVWMACHSAAFEDLR 2020.9
ESRNPGNAEIEDLIFLAR 2044.0
SYEQMETDGDRQNATEIR 2142.9
ND
NLPFEKSTIMAAFTGNTEGR 2184.1
LIQNSLTIEKMVLSAFDER 2207.2
LLQNSQIYSLIRPNENPAHK 2335.2
GVQIASNENMDNMGSSTLELR 2266.0
s at titers of 1×109 genome copies in the total volume of each sample, deposited
by trypsin.
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Fig. 1. Examples of MALDI-TOF mass spectra from whole inﬂuenza A virus tryptic
d
p
t
F
3
d
L
a
iigests of (A)H3N2and (B)H1N1. The shownm/z ratios are examples of the detected
eptides derived from inﬂuenza nucleoprotein.
rypsin auto-digestion fragments (shown as un-annotated peaks in
ig. 1).
.2. Identiﬁcation of inﬂuenza A viruses by LC–MS/MS
The same sample preparation procedure was followed as
escribed above, after which the peptides were subjected to
C–MS/MS. Virus identiﬁcation, including the sample preparation
nd analysis, was achieved in less than 6h for ten samples. In two
ndependent experiments, all ten inﬂuenza strains were correctlyf Virological Methods 213 (2015) 75–83 79
identiﬁed as either H1N1 or H3N2 inﬂuenza A virus, with an identi-
ﬁcation limit of 7×106 genome copies in the total sample volume
subjected to LC–MS/MS analysis (corresponding to a CT value of
approximately 30–32; Table 3). At this viral titer, the inﬂuenza
viruses were typed and subtyped based on the identiﬁcation of
peptides derived from the nucleoprotein protein, indicated in
boldface in Table 4. The nucleoprotein-derived peptides that were
identiﬁed repeatedly in at least 90% of the samples containing
≥7×106 viral genome copies are also shown in Table 4. In addition
to the peptides derived from NP, the LC–MS/MS analysis identiﬁed
peptides derived from M1, non-structural protein (NS1), HA,
and NA (Table S4). The amino acid sequence coverage of these
proteins (for each tenfold dilution of viral culture, an average
value of two independent experiments was calculated) is shown
in Table 3. Similar to the MALDI-TOF MS results, the identiﬁed
amino acid sequences of the ﬁve sequenced strains (BM1454,
BM1456, BM1457, BM1480, and BM1483) were in accordance
with their respective genome sequences. The LC–MS/MS spectra
also demonstrated proteins derived from cell lysates or culture
additives, such as actin, lectin, histone, and enolase (data not
shown). Moreover, most of the peptides detected with MALDI-TOF
MS were also identiﬁed with LC–MS/MS (Tables 2 and 4).
3.3. Identiﬁcation of respiratory viruses in mixed samples
Tenfold serial dilutions of strain BM1454 (H3N2) were mixed
with the corresponding dilution factor of RSV (mixture A), resulting
in an approximate 1:1 ratio of both strains. Similarly, in mixture B,
tenfold serial dilutions of strain BM1456 (H1N1) were mixed with
the corresponding dilution factor of hMPV, although the starting
titer of hMPV was 100 times lower than those of inﬂuenza and
RSV. The mixtures were treated according to the in-house devel-
oped sample preparation procedure, subjected to LC–MS/MS, and
subsequently analyzed as described for the samples containing a
single virus.
Using LC–MS/MS, both viruses in mixtures A and B were
identiﬁed simultaneously based on the peptides derived from
nucleoprotein proteins. The inﬂuenza strains were correctly typed
and subtyped from sample dilutions containing approximately
≥5.3×107 genome copies in the total sample volume subjected to
LC–MS/MS analysis. For inﬂuenza, peptides derived from M1, NS1,
HA, and NA proteins were also identiﬁed (Table 5). For the hMPV
and RSV strains, in addition to nucleoprotein-derived peptides,
those of matrix protein (M), matrix protein 2–1 (M2-1), phospho-
protein (P), and fusion glycoprotein (F) were also identiﬁed (Tables
5, S5, and S6). The identiﬁcation limit at which the RSV strain
was identiﬁed correctly, was 3.6×107 genome copy equivalents
in the total sample volume subjected to LC–MS/MS analysis (corre-
sponding to a CT value of approximately 28; Tables 5 and S1). For
hMPV, the identiﬁcation limit was 1.1×107 genome copy equiva-
lents in the total sample volume subjected to LC–MS/MS analysis
(corresponding to a CT value of approximately 28; Tables 5 and
S1). All of the identiﬁed peptide sequences of the tested inﬂuenza
A, RSV, and hMPV strains were conﬁrmed with their respective
genome sequence data (Supplementary Data, genomic and amino
acid sequences of sequenced strains).
3.4. Identiﬁcation of reconstituted clinical samples by LC–MS/MS
Tenfold serial dilutions of inﬂuenza A H1N1 (BM1456), H3N2
(BM1454), RSV (BM1450), and hMPV (BM1460) were spiked in
CyMol medium, containing material from a throat swab. These
reconstituted clinical samples were treated according to the
in-house developed sample preparation method, subjected to
LC–MS/MS and analyzed as described above. All the spiked respira-
tory viruses were identiﬁed. In both inﬂuenza A and RSV samples,
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Table 3
Inﬂuenza A viruses identiﬁed by LC–MS/MS.
Strains Subtype Titera Sequence coverageb (%) Identiﬁed asc
NP M1 NS1 HA NA
BM1454-55 H3N2 109 70 75 56 21 15 Inﬂuenza A H3N2
108 49 47 34 17 11
107 25 18 0 2 0
106 10 0 0 0 0
BM1456-57 H1N1 109 72 71 61 18 5 Inﬂuenza A H1N1
BM1480-85 108 56 49 39 10 4
107 44 30 15 0 0
106 14 0 0 0 0
a Tenfold dilution series of each tested inﬂuenza strain was prepared and analyzed by LC–MS/MS. Indicated are the total genome copies of the analyzed inﬂuenza virus
subjected to LC–MS/MS.
b Amino acid sequence coverage (%) of proteins determined by MASCOT, as based on identiﬁed peptides. Percentages are the averages of combined results for the H3N2
or H1N1 strain. Proteins were considered signiﬁcantly identiﬁed when the MASCOT score was ≥50 and when a minimum of three peptides each with a score of ≥20 was
identiﬁed. NP, nucleoprotein; M1, matrix protein; NS1, non-structural protein 1; HA, hemagglutinin; NA, neuraminidase;
c Identiﬁcation of type and subtype based on the highest MASCOT scores of nucleoprotein; thus, the given subtypes should be considered as indicative.
Table 4
Repeatedly LC–MS/MS-identiﬁed inﬂuenza A virus peptides derived from nucleoprotein at titers ≥7×106 genome copies.
H1N1 strains Observed m/z H3N2 strains Observed m/z
FQTAAQR 820.4 FQTAAQR 820.4
LSDYDGR 824.4 ND –
QDATEIR 831.4 QNATEIR 830.4
AMMDQVR 849.4 AMVDQVR 817.4
KTGGPIYR 890.5 KTGGPIYR 890.5
TRVAYER 893.5 TRSAYER 881.4
IDGKWMR 904.5 RVDGKWMR 1046.5
TGGPIYRR 918.5 TGGPIYRR 918.5
SRYWAIR 950.3 SGYWAIR 851.4
MCNILKGK 962.5 MCNILKGK 962.5
GKFQTAAQR 1005.5 GKFQTAAQR 1005.5
GVFELSDEK 1022.5 GVFELSDEK 1022.5
KTGGPIYRR 1046.6 DS 891.5
MVLSAFDER 1066.5 MVLSAFDER 1066.5
YLEEHPSAGK 1129.5 YLEEHPSAGK 1129.5
GVGTIAMELIR 1158.7 GIGTMVMELIR 1218.6
LIQNSITIER 1185.7 LIQNSLTIEK 1157.7
DS 849.4; 2044.0 AMVDQVRESR 1189.6
TSDMRTEVIR 1206.6 TSDMRAEIIR 1190.6
DS 1022.5 GRGVFELSDEK 1235.6
MVLSAFDERR 1222.6 MVLSAFDERR 1222.6
SYEQMETGGER 1285.5 SYEQMETDGDR 1329.5
HSNLNDATYQR 1317.6 HSNLNDATYQR 1317.6
EGYSLVGIDPFK 1323.7 EGYSLVGIDPFK 1323.7
FYIQMCTELK 1331.6 FYIQMCTELK 1331.6
NKYLEEHPSAGK 1371.7 NKYLEEHPSAGK 1371.7
MCSLMQGSTLPR 1379.6 MCSLMQGSTLPR 1379.6
LLQNSQVVSLMR 1386.8 DS 2334.2
ELILYDKEEIR 1419.7 ELVLYDKEEIR 1405.7
ATVMAAFSGNNEGR 1423.6 STIMAAFTGNTEGR 1454.7
YLEEHPSAGKDPK 1469.7 YLEEHPSAGKDPK 1469.7
MCSLMQGSTLPRR 1535.7 MCSLMQGSTLPRR 1535.7
ELILYDKEEIRR 1575.9 ELVLYDKEEIRR 1561.8
YLEEHPSAGKDPKK 1597.8 YLEEHPSAGKDPKK 1597.8
NPGNAEIEDLIFLAR 1670.9 NPGNAEIEDLIFLAR 1670.9
ASAGQISVQPTFSVQR 1674.8 ASAGQTSVQPTFSVQR 1662.9
NKYLEEHPSAGKDPK 1711.9 NKYLEEHPSAGKDPK 1711.9
MMESAKPEDLSFQGR 1724.8 MMEGAKPEEVSFR 1509.7
MCNILKGKFQTAAQR 1764.9 MCNILKGKFQTAAQR 1764.9
SQLVWMACHSAAFEDLR 2019.9 SQLVWMACHSAAFEDLR 2019.9
ESRNPGNAEIEDLIFLAR 2043.0 ESRNPGNAEIEDLIFLAR 2043.0
SYEQMETGGERQDATEIR 2098.9 SYEQMETDGDRQNATEIR 2141.9
SCLPACVYGLAVASGHDFER 2208.0 SCLPACAYGPAVSSGYDFEK 2177.9
RSYEQMETGGERQDATEIR 2255.0 ND –
LLQNSQVVSLMRPNENPAHK 2274.2 LLQNSQIYSLIRPNENPAHK 2334.2
GVQIASNENVETMDSNTLELR 2319.2 GVQIASNENMDNMGSSTLELR 2265.0
QANNGEDATAGLTHIMIWHSNLNDATYQR 3240.5 QANNGEDATAGLTHIMIWHSNLNDATYQR 3256.5
DS 1323.7; 2208.0 SCLPACAYGPAVSSGYDFEKEGYSLVGIDPFK 3483.6
Identiﬁcation data were extracted from MASCOT.
ND, peptide sequence not identiﬁed.
DS, identiﬁed sequence in another peptide.
The inﬂuenza viruses (≥7×106 genome copies) were typed and subtyped based mainly on the identiﬁcation of peptides derived from nucleoprotein (shown in bold).
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Table 5
Identiﬁed proteins of two different respiratory viruses from mixed samples. Mixture A contained H3N2 (BM1454) and RSV (BM1450). Mixture B contained H1N1 (BM1456)
and hMPV (BM1460).
Mix Titera Id. virusb Average sequence coverage of identiﬁed proteinsc (%)
NP M1 NS1 HA NA M2-1 F P
A 109 Inﬂuenza A/H3N2 63 74 16 15 4
RSV 21 43 53 9 55
108 Inﬂuenza A/H3N2 48 49 20 13 7
RSV 23 40 46 3 53
107 Inﬂuenza A/H3N2 18 34 0 5 0
RSV 14 0 23 0 0
B 109 Inﬂuenza A/H1N1 73 67 60 0 0
hMPVd 14 29 10 15 16
108 Inﬂuenza A/H1N1 49 33 39 0 0
hMPVd 8 18 10 9 18
107 Inﬂuenza A/H1N1 24 10 11 0 0
hMPVd 0 0 0 0 0
a Total genome copy number of the tested inﬂuenza virus and RSV in a total sample volume subjected to LC–MS/MS analysis.
b Identiﬁed virus.
c An average sequence coverage (%) of the identiﬁed protein was calculated from two independent experiments. A protein was considered identiﬁed when the MASCOT
score was ≥50 and when a minimum of three peptides with a score ≥20 was identiﬁed in the protein.
d The starting concentration of hMPV was 100 times lower than that for inﬂuenza and RSV.
NP, nucleoprotein;M1,matrix protein;NS1, non-structural protein 1;HA, hemagglutinin;NA, neuraminidase;M2-1,matrix protein; F, fusion glycoprotein; P, phosphoprotein.
Table 6
Identiﬁcation of viral proteins from reconstituted clinical material spiked with viruses.
Virus Titera Average sequence coverage of identiﬁed proteinsb (%)
NP M1 NS1 HA NA PA M2-1 F P
H3N2 109c 69 71 32 13 12 0 ND ND ND
108 25 27 0 0 0 0 ND ND ND
107 4 4 0 0 0 0 ND ND ND
H1N1 109c 68 77 71 0 7 3 ND ND ND
108 24 14 9 0 0 0 ND ND ND
RSV 109c 54 54 27.3 ND ND ND 35 9 31
108 3 35 ND ND ND ND 15 0 17
hMPV 107c 25 48 ND ND ND ND 16 28 19
106 0 0 ND ND ND ND 0 0 6d
Neg. control Throat swab 0 0 0 0 0 0 0 0 0
a Total genome copy number of the tested inﬂuenza virus and RSV in a total sample volume subjected to LC–MS/MS analysis.
b An average sequence coverage (%) of the identiﬁed protein was calculated from two independent experiments. A protein was considered identiﬁed when the MASCOT
score was ≥50 and when a minimum of two peptides with a score ≥20 was identiﬁed in the protein. NP, nucleoprotein; M1, matrix protein; NS1, non-structural protein 1;
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c Positive control; isolation of the virus was without throat swab material.
d Only in one of the two tested samples peptides were detected.
eptides derived from nucleoprotein, matrix protein M1, and non-
tructural protein NS1 were identiﬁed. In addition, in RSV samples
lso peptides derived from matrix protein M2-1 and phosphopro-
ein were identiﬁed. In one of the two tested hMPV samples, two
eptides derived from phosphoprotein were identiﬁed (Table 6).
he identiﬁcation limit at which inﬂuenza A H3N2 was detected,
as 1×107 genome copies in the total sample volume subjected to
C–MS/MS; for inﬂuenza A H1N1 and RSV this was approximately
×108 genome copies; for hMPV 1×107 genome copies.
. Discussion
The accurate and rapid identiﬁcation of inﬂuenza and other
espiratory viruses is important in combating outbreaks and
pidemics, detecting newly emerging viruses, and initiating pro-
hylaxis and early therapy. Antigen-detection and rRT-PCR tests
re used most frequently for the detection of viruses in the acute
hase. PCR-basedmethods can yield results within 3–8hwith high
ensitivity and speciﬁcity (Centers for Disease Control and Pre-
ention: Guidance for Clinicians on the Use of rRT-PCR and Other
olecular Assays for Diagnosis of Inﬂuenza Virus Infection, 2013),
hereas the rapid antigen-detection tests can even yield resultshosphoprotein.
within 15min. However, bothmethods feature drawbacks. (i) They
are target-directedandcanpotentiallymissnon-selectedor emerg-
ing pathogenic viruses that are not covered by the PCR primer sets
and antibodies used in the antigen-detection assays. For instance,
it was shown that a new type of human papillomavirus (HPV) was
not detected by a broad HPV-primer PCR system (Johansson et al.,
2013) and newly emerging mutations in the conserved region of
M1 prevented rRT-PCR detection of inﬂuenza A H1N1 and H3N2
from clinical specimens (Binnicker et al., 2013; Yang et al., 2014).
(ii) Multiple tests (different PCRs or PCR followed by sequencing)
are needed for (sub)typing and for detection of mixed infections.
(iii) The sensitivity of rapid antigen-detection tests is low. The com-
monly used Rapid Inﬂuenza Diagnostic Test (RIDT), although fast,
lacks accuracy and sensitivity (40–70%), resulting in a high per-
centage of false-negative results (Beck et al., 2012). Theoretically,
mass spectrometry-based systems could overcome these draw-
backs and they were already investigated for the identiﬁcation of
respiratory viruses. However, until now the used sample prepa-
ration methods were too laborious and time-consuming for mass
spectrometry to be an identiﬁcation method of clinical potential.
Therefore, in this study a rapid, generic and robust sample prepara-
tion method for mass spectrometry-based virus identiﬁcation was
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eveloped. Subsequently, the sensitivity of the combined proce-
ure of this sample preparation and mass spectrometry analysis
as determined.
Tenfold serial dilutions of ten cultured inﬂuenza A strains of two
ifferent subtypes, mixed samples of inﬂuenza A virus with either
MPV or RSV, and reconstituted clinical samples were treatedwith
he in-house developed sample preparation method without prior
uriﬁcation by laborious procedures, apart from standard removal
f cell debris. Subsequently, peptideswere subjected toMALDI-TOF
S and LC–MS/MS and identiﬁed by use of a web-based MASCOT
earch algorithm. To conﬁrm correct identiﬁcation, the amino acid
equences were compared to the corresponding DNA sequences,
btained by sequencing.
All of the inﬂuenza A strains were successfully identiﬁed to the
ubtype level by bothmass spectrometry systems. Identiﬁcation of
iruses was achieved within 3h with MALDI-TOF MS and within
h with LC–MS/MS, excluding the time necessary for culturing the
iruses. Sensitivity of MALDI-TOF MS was lower (detection limit
f 1×109; Table 1) compared to LC–MS/MS (detection limit of
×106; Table 3); the latter corresponding to a CT value of 30–32.
Earlier studies have already shown that it is possible to identify
ighly pure and/or concentrated inﬂuenza A viruses with MALDI-
OF MS, MALDI-FT-ICR MS or LC–MS/MS (Schwahn et al., 2009a,b,
010a,b; Chou et al., 2011; Jang et al., 2011; Nguyen and Downard,
013; Fernandes and Downard, 2014; Li et al., 2014). However,
he sample preparation methods used were time-consuming (up
o 24h) and laborious, and are therefore not suitable for rapid
pplications. In these studies, the samenucleoprotein-derivedpep-
ides were found among the identiﬁed viral peptides as detected
ere (Schwahn et al., 2009a,b; Li et al., 2014), which indicates
hat with the in-house developed sample preparation method,
omparable results could be achieved in a much shorter time.
urthermore, in the developed sample preparation method, prior
uriﬁcation or extended concentration of cultured viruses, for
xample by applying ultracentrifugation, is not required for the
dentiﬁcation of viral proteins in the presence of other viral or
on-viral proteins. The sample preparation time was signiﬁcantly
educed to approximately 1.5h by the introduction of REDS for
apid reduction, alkylation, precipitation, and trypsin digestion.
he tenfold serial dilutions of cultured viruses were prepared in
yMol, a collection, transport and preservation medium known
or its compatibility with multiple diagnostic platforms including
ytology and molecular diagnostics (Luinstra et al., 2011). Sus-
ending viruses in CyMol signiﬁcantly (approximately 100-fold)
mproved the identiﬁcation limit compared to theother testedsolu-
ions, such as ammonium bicarbonate, NTE buffer (100mM NaCl,
0mM Tris–HCl [pH 7.5], 1mM EDTA), PBS (phosphate buffered
aline), and a universal transport medium (UTM-RT; data not
hown).
Besides monocultures of inﬂuenza A strains, mixed samples
f inﬂuenza A virus with either hMPV or RSV were subjected to
ALDI-TOF MS and LC–MS/MS. Viruses were identiﬁed simulta-
eously and speciﬁcally by LC–MS/MS (Table 5), with a detection
imit of 5.3×107 for inﬂuenza A (H1N1 and H3N2), 3.6×107 for
SV, and 1.1×107 genome copies for hMPV. Identiﬁcation was not
ossible by MALDI-TOF MS due to its low sensitivity. In addition
o monocultures and mixed samples, throat swabs spiked with
nﬂuenza A, hMPV or RSV were subjected to LC–MS/MS. All the
piked viruses were identiﬁed, with detection limits of 107, 108,
nd 107 genome copies for inﬂuenza A H3N2, inﬂuenza A H1N1
nd RSV, and hMPV, respectively. These results demonstrate that
C–MS/MS is not only able to identify monocultures of viruses, but
an also discriminate between two viruses in the same sample and
an identify a virus from a sample containing human proteins orig-
nating froma throat swab. Sensitivity of LC–MS/MS appeared to be
ower when mixed samples or reconstituted samples were tested.f Virological Methods 213 (2015) 75–83
Viral loads in clinical samples vary depending on the type of
respiratory material, subtype of the virus, severity and phase of
infection, and host factors, such as immunity. In general, viral loads
fall within the range of 104–106 genome copies/ml (Ngaosuwankul
et al., 2010; Lee et al., 2011). In addition, in a recent pan-European
survey (Nuttall et al., 2011), the average CT values for inﬂuenza
virus, RSV, and hMPV detected in patients were 29, 29, and 30,
respectively (Coenjaerts, F.E.J., personal communication). There-
fore, the ultimate identiﬁcation limit of a mass spectrometry
method should reach 104 genome copies/ml for direct clinical
application. The sensitivity of the developed sample preparation
method in combination with LC–MS/MS is 100-fold lower and
therefore not good enough for direct application in virological diag-
nostics. For detection of viruses from clinical samples, viral culture
is needed before samples can be prepared and analyzed. Because
culturing is required, viable virus has to be recovered and success-
fully grown. For application in virological diagnostics, sensitivity
should be increased by developing techniques that enable fast and
efﬁcient virus concentration andpuriﬁcation fromrespiratory sam-
ples. Furthermore,mass spectrometry systems should be improved
to increase sensitivity. In the meanwhile, keeping the drawbacks
into mind this in-house developed sample preparation method
in combination with LC–MS/MS could be experimentally used for
patients with suspicion of a respiratory infection where routine
diagnostics are negative.
The identiﬁcation of the inﬂuenza A strains, RSV and hMPV was
based on detection of peptides derived from different proteins. All
these identiﬁed peptides were found to be encoded in the corre-
sponding genome sequences. MALDI-TOF MS and LC–MS/MS both
detected nucleoprotein-derived peptides. In addition, LC–MS/MS-
identiﬁed peptides derived from other viral proteins, namely M1,
NS1, HA, and NA proteins of inﬂuenza viruses and M, M2-1, P,
and F proteins of RSV and hMPV. The identiﬁcation of peptides
from different proteins not only accomplishes identiﬁcation but
also potentially delivers information about virulence, resistance to
antiviral medications, and/or transmission efﬁciency. For instance,
an amino acid substitution in nucleoprotein (M136L)was shown to
enhance human-to-human transmission (Zhou et al., 1999). Inter-
estingly, one of the identiﬁed nucleoprotein-derived peptides, i.e.,
QANNGEDATAGLTHIMIWHSNLNDATYQR, contained this substitu-
tion. This peptide was found in all of the tested inﬂuenza strains
(Table 4), suggesting that these strains might exhibit increased
human-to-human transmission efﬁciency.
In conclusion, mass spectrometry systems have been investi-
gated for the identiﬁcation of highly pure and/or concentrated
inﬂuenza A viruses. However, used sample preparation methods
were laborious and time-consuming. The developed sample prepa-
ration method in combination with LC–MS/MS allowed rapid and
reliable identiﬁcation of cultured respiratory viruses and viruses
spiked in throat swabs. To introduce this LC–MS/MS based iden-
tiﬁcation method in virological diagnostics, sensitivity must be
improved up to 100-fold and clinical samples have to be tested. The
combination of an improved mass spectrometry technique and/or
clinical sample preparation method allowing direct identiﬁcation
of viruses fromclinical sampleswill be an importantnewdiagnostic
tool in clinical virology.
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